Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 2/20 | 0.36 |
| ▸ | CDC7 | O00311 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 4/20 | 0.34 |
| ▸ | NPC1 | O15118 | 3/20 | 0.34 |
| ▸ | FABP4 | P15090 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | KDR | P35968 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5573751 | 1.00 | APP (0.36) | APPCDC7RAB9ANPC1FABP4 | |
| SCHEMBL5630150 | 0.90 | NPC1 (0.39) | APPCDC7NPC1FABP4CLK4 | |
| SCHEMBL14422272 | 0.90 | NPC1 (0.39) | APPCDC7NPC1FABP4CLK4 | |
| SCHEMBL5574027 | 0.86 | DYRK3 (0.34) | RAB9ANPC1MEN1KMT2ACLK4 | |
| SCHEMBL5629675 | 0.86 | DYRK3 (0.34) | RAB9ANPC1MEN1KMT2ACLK4 | |
| SCHEMBL14422273 | 0.86 | PDE10A (0.38) | APPRAB9ANPC1MEN1KMT2A | |
| SCHEMBL5631576 | 0.86 | PDE10A (0.38) | APPRAB9ANPC1MEN1KMT2A | |
| SCHEMBL5573823 | 0.86 | ELANE (0.40) | MEN1KMT2AALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL5573825 | 0.86 | ELANE (0.40) | MEN1KMT2AALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL5570175 | 0.83 | PDE10A (0.34) | RAB9ANPC1CLK4HPGDL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1805174-A1 | 1,5-NAPHTHYRIDINE AZOLIDINONES HAVING CDK1 ANTIPROLIFERATIVE ACTIVITY | F.HOFFMANN-LA ROCHE AG (CH) | 2007-07-11 | — | — | EP | claimed |
| WO-2006040052-A1 | 1,5-NAPHTHYRIDINE AZOLIDINONES HAVING CDK1 ANTIPROLIFERATIVE ACTIVITY | F. HOFFMANN-LA ROCHE AG (CH) | 2006-04-20 | — | — | WO | claimed |
| US-20060084673-A1 | 1,5-naphthyridine azolinone | LIU JIN-JUN | 2006-04-20 | — | — | US | claimed |
| US-7268231-B2 | 1,5-Naphthyridine azolinone | HOFFMANN-LA ROCHE INC. (US) | 2007-09-11 | — | — | US | disclosed |
| EP-1805174-A1 | 1,5-NAPHTHYRIDINE AZOLIDINONES HAVING CDK1 ANTIPROLIFERATIVE ACTIVITY | F.HOFFMANN-LA ROCHE AG (CH) | 2007-07-11 | — | — | EP | disclosed |
| WO-2006040052-A1 | 1,5-NAPHTHYRIDINE AZOLIDINONES HAVING CDK1 ANTIPROLIFERATIVE ACTIVITY | F. HOFFMANN-LA ROCHE AG (CH) | 2006-04-20 | — | — | WO | disclosed |
| US-20060084673-A1 | 1,5-naphthyridine azolinone | LIU JIN-JUN | 2006-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084673-A1 | 1,5-naphthyridine azolinone | CDK1, CDK15, CDK14 | APP 4784/4885CDC7 36/4885RAB9A 3599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.